Tangram Therapeutics has advanced its investigational MASH treatment TGM-312 into Part B of the ongoing Phase 1/2 RESTORE-MASH trial, marking the programme’s transition from healthy-volunteer testing to multiple ascending doses in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH).

TGM-312 is a liver-directed GalNAc-conjugated siRNA (GalNAc-siRNA) designed to selectively silence SLC25A5, a target identified through Tangram’s proprietary network biology approach combined with MASH/MASLD population genetic data. The investigational therapy is designed to address inflammation and steatosis, two key drivers of MASH, with potential for infrequent subcutaneous dosing, including a quarterly regimen.

The trial’s progression follows a favourable independent Data Monitoring Committee review. TGM-312 has so far been administered across four healthy-volunteer cohorts without serious or severe adverse events. Interim data from MASH patients are expected in 2027.

Tangram said preclinical studies have shown reductions in liver disease activity, hepatic inflammation and fibrosis progression, both as monotherapy and in combination with approved and emerging MASH therapies.

Alongside the clinical milestone, Tangram has appointed Dr. Sonya Montgomery as Chief Development Officer. Montgomery brings more than 25 years of experience in drug development and portfolio strategy across pharma and biotechnology, including leadership roles at Pfizer, ProQR, Gyroscope Therapeutics, Evox Therapeutics and OSE Immunotherapeutics.

Montgomery will lead the advancement of Tangram’s clinical pipeline, including TGM-312 and TGM-148, the company’s programme targeting bleeding disorders.